Bank of New York Mellon Corp bought a new stake in shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM – Free Report) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor bought 20,232 shares of the company’s stock, valued at approximately $356,000.
Analyst Upgrades and Downgrades
Separately, Royal Bank of Canada raised their price objective on shares of Contineum Therapeutics from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Wednesday, August 14th.
View Our Latest Research Report on Contineum Therapeutics
Contineum Therapeutics Price Performance
Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.02). On average, equities research analysts forecast that Contineum Therapeutics, Inc. will post -2.04 EPS for the current year.
Contineum Therapeutics Profile
Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).
Featured Stories
- Five stocks we like better than Contineum Therapeutics
- 3 REITs to Buy and Hold for the Long Term
- Should You Invest in Treasury Bills?
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Analysts Think There’s Still Time to Get in on Edgewise, Up 332%
- Best Stocks Under $5.00
- 3 Stocks Raising Dividends 4X Higher Than Inflation
Want to see what other hedge funds are holding CTNM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Contineum Therapeutics, Inc. (NASDAQ:CTNM – Free Report).
Receive News & Ratings for Contineum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Contineum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.